Author: MS Trust
The MS Trust is worried that NICE's draft guidance on fingolimod (Gilenya) will discriminate against some people with MS.
NICE (National Institute of Health and Clinical Excellence) issued its draft guidance on 5 August 2011. The guidance stated that fingolimod is not recommended for the treatment of relapsing remitting multiple sclerosis.
The MS Trust's response to the consultation on the draft guidance draws attention to a number of concerns.
